by EpicentRx | Jul 19, 2023 | Blog
As Shakespeare might have put it had he lived in 2023 amid the record-breaking heatwave that has gripped parts of Eastern Asia, Europe, and North America, “Now is the summer of our discontent”. Or, as Glenn Frye, founding member of the Eagles, famously voiced, “The...
by EpicentRx | Jul 19, 2023 | Blog
Cisplatin (cis-diamminedichloroplatinum) plus intensity-modulated radiation therapy, also called IMRT, is the mainstay of treatment for head and neck cancer (HNC). In a randomized Phase 2 trial called PREVLAR, the addition of nibrozetone (RRx-001) to chemoradiation...
by EpicentRx | Jul 18, 2023 | Blog
Necessity is the mother of invention, so the saying goes. Sometimes it is also the father. The father in this case is Dr. Tony Reid, previously the Primary Investigator (PI) on the first-in-human (FIH) clinical trial for nibrozetone (RRx-001) (see blog post entitled...
by EpicentRx | Jul 17, 2023 | Blog
“The meek shall inherit…the Words of the Week.” NO Definition: Noun: A colorless gas and a stable free radical that nibrozetone (RRx-001) generates at extremely high levels in hypoxic/reductive environments. Example sentence: “NO laughing matter: NO, which stands for...
by EpicentRx | Jul 14, 2023 | Blog
Ok, so that just happened. Elon Musk challenged Mark Zuckerberg to, ahem, a measuring contest. Well, not to wade headlong (or with another anatomical part) into this debate, but let’s just say, Mr. Musk, that size isn’t everything. Case in point: AdAPT-001. This is an...
